cerebral infaction
Conditions
Interventions
None listed
Sponsors
SCIENCE Study Protocol Comittee
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: first onset symptomatic cerebral infarction within 2 months after onset primary treated by each hospital registered MRI acceptable mRS Grade0-4 3-year follow up executable prior written informed consent
Exclusion criteria
Exclusion criteria: recurred symptomatic cerebral infarction medicatin of antiplatelet drugs before onset moyamoya disease, AVM, AN, dural AVF previous cerebral contusion previous craniotomy and/or burr hole surgery future surgery and/or intervention for brain and heart previous symptomatic cerebral hemorrhage, other hemorrhagic disease, coagulopathy present malignancy platelet count<10000/m3 liver dysfunction (AST>100IU/L, ALT>100IU/L) renal dysfunction (Cre>3mg/dl) future moving, diffculties for follow-up amyloid angiopathy participants in other intervening clinical research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptomatic cerebral infarction and symptomatic cerebral hemorrhage | — |
Secondary
| Measure | Time frame |
|---|---|
| number of cerebral microbleeds, Grade of DWMH and PVH, ADL, event by antiplatelet drugs, symptom of upper GI and QOL, other cerebrovascular event, cardiovascular event, death | — |
Countries
Japan
Outcome results
None listed